Abnormal fragile histidine triad expression in advanced cervical cancer and evaluation of its utility as a prognostic factor

Oncology

Volumn 65, Issue 1, 2003, Pages 89-93

  Machida, Shizuo ^a   Ohwada, Michitaka ^a   Saga, Yasushi ^a   Suzuki, Mitsuaki ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Cervical cancer; Fragile histidine triad; Prognosis; Radiosensitivity; Squamous cell carcinoma antigen

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; EVALUATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MATHEMATICAL COMPUTING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIOSENSITIVITY; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; UTERINE CERVIX CARCINOMA;

ACID ANHYDRIDE HYDROLASES; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; JAPAN; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PARAFFIN EMBEDDING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; UTERINE CERVICAL NEOPLASMS;

EID: 0038309272     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000071209     Document Type: Article

References (25)

1. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, Croce CM, Huebner K: The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) break point, is abnormal in digestive tract cancers. Cell 1996;84:587-597.
2. nA), a novel class of signalling molecules? FEBS Lett 1998;427:157-163.
3. Croce CM, Sozzi TG, Huebner K: Role of FHIT in human cancer. J Clin Oncol 1999;17:1618-1624.
4. Segawa T, Sasagawa T, Yamazaki H, Sakaike J, Ishikawa H, Inoue M: Fragile histidine triad transcription abnormalities and human papil-lomavirus E6-E7 mRNA expression in the development of cervical carcinoma. Cancer 1999;85:2001-2010.
5. Birrer MJ, Hendricks D, Farley J, Sundburg MJ, Boneme T, Walts MJ, Geradts J: Abnormal fhit expression in malignant and premalignant lesions of the cervix. Cancer Res 1999;59:5270-5274.
6. Greenspan DL, Connolly DC, Wu R, Lei RY, Vogelstein JT, Kim YT, Mok JE, Munoz N, Bosch FX, Shah K, Cho KR: Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res 1997;57:4692-4698.
7. Druck T, Berk L, Huebner K: FHITness and cancer. Oncol Res 1998;10:341-345.
8. Hao XP, Willis JE, Pretlow TG, Rao JS, MacLennan GT, Talbot IC, Pretlow TP: Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions. Cancer Res 2000;60:18-21.
9. Ozaki K, Enomoto T, Yoshino K, Fujita M, Buzard GS, Kawano K, Yamasaki M, Murata Y: Impaired FHIT expression characterizes serous ovarian carcinoma. Br J Cancer 2001;85:247-254.
10. Ozaki K, Enomoto T, Yoshino K, Hongbo S, Nakamura T, Fujita M, Kuragaki C, Sakata M, Kurachi H, Murata Y: fhit alterations in endometrial carcinoma and hyperplasia. Int J Cancer 2000;85:306-312.
11. Segawa T, Sasagawa T, Saijoh K, Inoue M: Clinicopathological significance of fragile histidine triad transcription protein expression in endometrial carcinomas. Clin Cancer Res 2000;6:2341-2348.
12. Capuzzi D, Santoro E, Hauck WW, Kovatich AJ, Rosato FE, Baffa R, Huebner K, McCue PA: Fhit expression in gastric adenocarcinoma: Correlation with disease stage and survival. Cancer 2000;88:24-34.
13. Noguchi T, Muller W, Wrirtz HC, Willers R, Gabbertt HE: FHIT gene in gastric cancer: Association with tumor progression and prognosis. J Pathol 1999;188:378-381.
14. Shimada Y, Sato F, Watanabe G, Yamasaki S, Kato M, Maeda M, Imamura M: Loss of fragile histidine triad gene expression is associated with progression of esophageal squamous cell carcinoma, but not with the patient's prognosis and smoking history. Cancer 2000;89:5-11.
15. Tomizawa Y, Nakajima T, Kohno T, Saito R, Yamaguchi N, Yokota J: Clinicopathological significance of Fhit protein expression in stage I non-small cell lung carcinoma. Cancer Res 1998;58:5478-5483.
16. Yang Q, Yoshimura G, Suzuma T, Tamaki T, Umemura T, Nakamura M, Nakamura Y, Wang X, Mori I, Sakurai T, Kakudo K: Clinicopathological significance of fragile histidine triad transcription protein expression in breast carcinoma. Clin Cancer Res 2001;7:3869-3873.
17. Nakagawa S, Yoshikawa H, Kimura M, Kawana K, Matsumoto K, Onda T, Kino N, Yamada M, Yasugi T, Takeyani Y: A possible involvement of aberrant expression of the FHIT gene in the carcinogenesis of squamous cell carcinoma of the uterine cervix. Br J Cancer 1999;79:589-594.
18. Krivak TC, McBroom JW, Seidman J, Venzon D, Crothers B, MacKoul PJ, Rose GS, Carlson JW, Birrer MJ: Abnormal fragile histidine triad (FHIT) expression in advanced cervical carcinoma: Poor prognostic factor. Cancer Res 2001;61:4382-4385.
19. Hendricks DT, Taylor R, Reed M, Birrer MJ: FHIT gene expression in human ovarian, endometrial, and cervical cell lines. Cancer Res 1997;57:2112-2115.
20. Helland A, Kraggerud SM, Kristensen GB, Holm R, Abeler VM, Huebner K, Borressen-Dale AL, Lothe RA: Primary cervical carcinomas show 2 common regions of deletion at 3P,1 within the FHIT gene: Evaluation of allelic imbalance at FHIT, RB1 and TP53 in relation to survival. Int J Cancer 2000;88:217-222.
21. Yazigi R, Munoz AK, Richardson B, Risser R: Correlation of squamous cell carcinoma antigen levels and treatment response in cervical cancer. Gynecol Oncol 1991;41:135-138.
22. Ngan HY, Chan SY, Wong LC, Choy DT, Ma HK: Serum squamous cell carcinoma antigen in the monitoring of radiotherapy treatment response in carcinoma of the cervix. Gynecol Oncol 1990;37:260-263.
23. Ji L, Fang B, Yen N, Fong K, Minna JD, Roth JA: Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 1999;59:3333-3339.
24. Roz L, Gramegna M, Ishii H, Croce CM, Sozzi G: Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines. Proc Natl Acad Sci USA 2002;19:3615-3620.
25. Wu R, Connolly DC, Dunn RL, Cho KR: Restored expression of fragile histidine triad protein and tumorigenicity of cervical carcinoma cells. J Natl Cancer Inst 2000;92;338-344.